Market Closed -
Hong Kong S.E.
04:08:20 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
4.87
HKD
|
-1.81%
|
|
+4.51%
|
+13.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,489
|
1,431
|
5,301
|
2,302
|
4,078
|
4,611
|
-
|
-
|
Enterprise Value (EV)
1 |
1,489
|
1,431
|
5,301
|
2,302
|
4,078
|
4,611
|
4,611
|
4,611
|
P/E ratio
|
9.33
x
|
13.3
x
|
14.7
x
|
10.4
x
|
10.1
x
|
9.96
x
|
8.58
x
|
7.62
x
|
Yield
|
-
|
-
|
3.05%
|
3.36%
|
3.49%
|
3.59%
|
4.11%
|
4.72%
|
Capitalization / Revenue
|
-
|
-
|
1.79
x
|
0.81
x
|
1.29
x
|
1.31
x
|
1.18
x
|
1.07
x
|
EV / Revenue
|
-
|
-
|
1.79
x
|
0.81
x
|
1.29
x
|
1.31
x
|
1.18
x
|
1.07
x
|
EV / EBITDA
|
-
|
-
|
8.43
x
|
5.07
x
|
5.88
x
|
5.85
x
|
5.26
x
|
4.8
x
|
EV / FCF
|
-
|
-
|
13.8
x
|
-
|
-
|
7.79
x
|
7.17
x
|
6.52
x
|
FCF Yield
|
-
|
-
|
7.24%
|
-
|
-
|
12.8%
|
14%
|
15.3%
|
Price to Book
|
-
|
-
|
2.25
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
967,077
|
960,227
|
956,941
|
954,991
|
948,298
|
946,898
|
-
|
-
|
Reference price
2 |
1.540
|
1.490
|
5.540
|
2.410
|
4.300
|
4.870
|
4.870
|
4.870
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
2,955
|
2,830
|
3,172
|
3,515
|
3,906
|
4,319
|
EBITDA
1 |
-
|
-
|
628.7
|
454.1
|
693.9
|
787.7
|
877
|
961.5
|
EBIT
1 |
-
|
-
|
493.9
|
306.1
|
538.7
|
619.8
|
710.3
|
796.3
|
Operating Margin
|
-
|
-
|
16.71%
|
10.82%
|
16.98%
|
17.63%
|
18.18%
|
18.44%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
464.1
|
290.1
|
509.6
|
592.5
|
690.7
|
781.8
|
Net income
1 |
161.6
|
107.8
|
360.8
|
220.5
|
404.1
|
463.3
|
538.6
|
609.8
|
Net margin
|
-
|
-
|
12.21%
|
7.79%
|
12.74%
|
13.18%
|
13.79%
|
14.12%
|
EPS
2 |
0.1650
|
0.1120
|
0.3770
|
0.2310
|
0.4240
|
0.4890
|
0.5675
|
0.6395
|
Free Cash Flow
1 |
-
|
-
|
383.7
|
-
|
-
|
591.9
|
643.5
|
707.7
|
FCF margin
|
-
|
-
|
12.98%
|
-
|
-
|
16.84%
|
16.47%
|
16.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
61.03%
|
-
|
-
|
75.14%
|
73.38%
|
73.6%
|
FCF Conversion (Net income)
|
-
|
-
|
106.34%
|
-
|
-
|
127.74%
|
119.47%
|
116.06%
|
Dividend per Share
2 |
-
|
-
|
0.1690
|
0.0810
|
0.1500
|
0.1750
|
0.2000
|
0.2300
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
384
|
-
|
-
|
592
|
644
|
708
|
ROE (net income / shareholders' equity)
|
-
|
-
|
16.6%
|
-
|
16.3%
|
16.8%
|
17.2%
|
17.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
10.4%
|
-
|
10.8%
|
12.2%
|
12.7%
|
12.8%
|
Assets
1 |
-
|
-
|
3,457
|
-
|
3,746
|
3,798
|
4,241
|
4,764
|
Book Value Per Share
|
-
|
-
|
2.460
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
141
|
-
|
-
|
100
|
100
|
100
|
Capex / Sales
|
-
|
-
|
4.79%
|
-
|
-
|
2.84%
|
2.56%
|
2.32%
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
-
|
Last Close Price
4.87
HKD Average target price
7.19
HKD Spread / Average Target +47.64% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.26% | 589M | | +1.84% | 24.07B | | -6.34% | 16.75B | | +10.34% | 10.18B | | -17.75% | 2.06B | | +6.38% | 1.79B | | +41.47% | 1.73B | | 0.00% | 400M | | +27.40% | 135M | | +21.80% | 93.49M |
Medical Prosthetics
|